|Day's Range||0.03 - 0.03|
|52 Week Range||0.03 - 0.05|
|PE Ratio (TTM)||-7.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Prima is running trials to treat breast cancer and skin cancer using combinations of its drug IMP321.
Prima (PBMD) dosed the first patient in the enlarged randomized phase of the phase IIb study -- AIPAC -- on IMP321 for the treatment of metastatic breast cancer.
Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.